Another oral pan-RAS inhibitor known as RMC-7977, with high selectivity for GTP-bound KRAS, HRAS, and NRAS (regardless of mutational status), effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells [44]. The gene discussed is KRAS; the disease is cancer.